Dual incretin agonist: difference between revisions
Diff·revision 10 → 11·11:11, 17 Nov 2024
Difference between revision 10 and revision 11 of Dual incretin agonist. 1 line changed; the page grew by 113 bytes.
| Revision 10 — 06:27, 1 Nov 2024 SafetySignalSid (talk) de-orphan 3,352 bytes ±0 | Revision 11 — 11:11, 17 Nov 2024 GroupBuyGalen (talk) move the trade-name history out of the lead and into §Regulatory history 3,465 bytes +113 | ||
|---|---|---|---|
| 7 | | Marketed example = [[Tirzepatide]] (2022) | 7 | | Marketed example = [[Tirzepatide]] (2022) |
| 8 | }} | 8 | }} |
| + | 9 | {{hatnote|For the marketed example, see [[Tirzepatide]]. For three-receptor molecules, see [[Triple agonist]].}} | |
| 9 | 10 | ||
| 10 | A '''dual incretin agonist''' is a single engineered peptide that activates two receptors of the glucagon-secretin family — most often the receptor for [[Glucose-dependent insulinotropic polypeptide]] and the [[GLP-1 receptor]] — in a ratio fixed by its chemistry rather than by a prescriber's choice of two drugs.{{r|finan2013}} | 11 | A '''dual incretin agonist''' is a single engineered peptide that activates two receptors of the glucagon-secretin family — most often the receptor for [[Glucose-dependent insulinotropic polypeptide]] and the [[GLP-1 receptor]] — in a ratio fixed by its chemistry rather than by a prescriber's choice of two drugs.{{r|finan2013}} |